Welcome to MolDiag-PaCa

1. Andren-Sandberg A, Neoptolemos JP. Resection for pancreatic cancer in the new millennium Pancreatology. 2002; 2: 431-9.

2. Bramhall, S. R., W. H. Allum, et al. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg 1995; 82: 111-5.

3. Greenlee, R. T., M. B. Hill-Harmon, et al. Cancer statistics, 2001. CA Cancer J Clin 2001; 51: 15-36 128

4. Heinmöller E, Dietmaier W, Zirngibl H, Heinmöller P, Scaringe W, Jauch K-W, Hofstadter F, Ruschoff J. 2000. Molecular analysis of microdissected tumors and preneoplastic intraductal lesions in pancreatic carcinoma. Am J Pathol 157:83–92.

5. Hruban RH, Adsay NV, Albores-Saavedra J, Compton C, Garrett ES, Goodman SN, Kern SE, Klimstra DS, Klöppel G, Longnecker DS, Lüttges J, and Offerhaus GJ. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 2001, 25: 579-586.

6. Luttges J et al. Update on the pathology and genetics of exocrine pancreatic tumors with ductal phenotype: precursor lesions and new tumor entities. (2001) Dig Dis 19: 15-23.

7. Lüttges J, Galehdari H, Bröcker V, Schwarte-Waldhoff I, Henne-Bruns D, Klöppel G, Schmiegel W, and Hahn SA. Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis. Am J Pathol 2001, 158: 1677-1683.

8. Moskaluk CA, Hruban RH, and Kern SE. p16 and K-ras mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Research 1997, 57: 2140-2143.

9. Mueller F et al. KOC is a novel molecular indicator of malignancy. Br J Cancer 88: 699-701 (2003).

10. Neoptolemos JP et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomised controlled trial. Ann Surg 2001b; 234:758-768.

11. Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001; 358: 1576-1585.

12. Neoptolemos JP et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200-10.

13. Parkin, D. M., F. I. Bray, et al. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37 Suppl 8: 4-66.

14. Saad, SD, Hoff, PM Molecular-Targeted Agents in Pancreatic Cancer Cancer Control: 11, 32-39, 2004

15. Sener, S. F., A. Fremgen, et al. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database J Am Coll Surg 1999; 189: 1-7.

16. Shore S, Raraty M, Ghaneh P, et al. Chemotherapy for pancreatic cancer. Aliment Pharmacol Ther. 2003; 18:1049-1069.

17. Silvermann DT, et al. Cigarette smoking and pancreas cancer: a case-control study based on direct interviews. J Natl Cancer Inst 1994, 86: 1510-1516.

18. Sohn, T. A., C. J. Yeo, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4: 567-79.

19. Vimalachandran, D, Ghaneh,P., Costello,E., Neoptolemos,JP. Genetics and Prevention of Pancreatic Cancer. Cancer Control 11, 6-14, 2004.

20. Yamano, M, Fujii, H., Takagaki, T., Kadowaki, N., Watanabe, H., Sjirai, T. Genetic Progression and Divergence in Pancreatic Carcinoma. Am J Path  2000; 156:2123-2133

21. Yeo TP, Hruban RH, Leach SD, Wilentz RE, Sohn TA, Kern SE, Iacobuzio-Donahue CA, Maitra A, Goggins M, Canto MI, Abrams RA, Laheru D, Jaffee EM, Hidalgo M, and Yeo CJ. Pancreatic cancer. Curr Probl Cancer 2002, 26: 176-275. 133

>> Publications

Responsible scientists

Francisco X. Real
Epithelial Carcinogenesis Group - Molecular Pathology Programme
N�ria Malats
Human Cancer Genetics Programme - Genetic & Molecular Epidemiology

Role in the integrated project:
The main contribution of our group will be to the design and conduct of studies aimed at determining the contribution of inherited genetic factors to the development of pancreatic cancer, mainly using case-control studies and high throuput genotyping strategies. In addition, we will contribute to the generation of resources for testing novel diagnostic/prognostic strategies using RNA-based or protein-based techniques.

Major interests related to pancreas cancer:
  • Genetic epidemiology of pancreas cancer
  • Molecular epidemiology of pancreas cancer
  • Development of novel mouse models of pancreas cancer
  • Differentiation control and pancreas cancer development
  • Role of tPA in pancreas cancer development and progression

Group members:
  • Francisco X. Real
  • N�ria Malats
  • Gema Carretero
  • Ana Alfaro
  • Ongoing recruitment of personnel
  • Roger Milner
  • Cristiane Nascimento-Murta.

  • Paco Real        This email address is being protected from spambots. You need JavaScript enabled to view it.
  • N�ria Malats    This email address is being protected from spambots. You need JavaScript enabled to view it.

>> Publications

Professor Johan Permert
Key person 1.

Overall research programme:

The group for treatment and research of pancreatic diseases within the unit of Upper Abdominal Surgery at the Department of Surgical Gastroenterology is one of the leading centers for pancreatic surgery and research in Scandinavia. Currently we perform annually app. 70-80 pancreatic resections. As a result of structural changes of Stockholm health care and of agreements with neighbouring counties our unit (Div. of Upper Abdominal Surgery, Karolinska University Hospital at Huddinge) has been given the task to perform all pancreatic surgery performed in the counties of Stockholm, Södermaland, Västmaland and Gotland. This represents an area of 3,2 million inhabitants. This gives us access to the major fraction of patients with pancreatic cancer, periampulary cancer and other 117 MolDiag-Paca PL018771 Draft date 26.06.2006 malignancies involving pancreas from this population. With help of The Swedish Cancer Registry we will be able to perform population-based collection of patient information, plasma and tissue from patients with pancreatic cancer. Calculations based on the incidence of pancreatic cancer indicate that we will get access s to more than 200 patients with pancreatic cancer every year. Our research group has a longstanding experience of research in different aspects of pancreatic cancer. We have concentrated on metabolic aspects of this disease and have an advanced program involving both clinical studies and experimental research regarding the mechanism of cachexia in pancreatic cancer. An extensive experience in using patient material in research is documented. We have recently involved epidemiological expertise to expand our work into this field.

Role in the integrated project:
The participant has a unique possibility to perform population based sampling of patient information’s, plasma and tissues from all patients with pancreatic caner of an area of 3.2 million inhabitants. This material will be made available to the consortium. We will also contribution with cases and controls to the planned case/control-studies of WP 1.We will act as a clinical partner to the partners of other workpackages (WP3-5) in testing diagnostic tools and contribute in clinical studies in WP7.

Group members:
  • Professor Jutta Lüttges (key person 2)
  • M.D., Ph.D Magnus Nilsson (key person 3)
  • Ass. Professor Weimin Ye
  • M.D., Ph.D Bengt Isaksson
  • Ass. Professor Wang Feng
  • M.D., Ph.D Lisa Strömmer

  1. Genotyping Microarray (Gene Chip) for the ABCR (ABCA4) Gene. K. Jaakson, J. Zernant, M. Kulm, A. Hutchinson, N. Tonisson, D. Glavac�, M. Ravnik-Glavac�, M. Hawlina, M.R. Meltzer, R.C. Caruso, F. Testa, A. Maugeri, C.B. Hoyng, P. Gouras, F. Simonelli, R.A. Lewis, J.R. Lupski, F.P.M. Cremers, and R. Allikmets. Hum Mutant 2003, Vol. 22, pp. 395-403.
  2. Evaluation of a microarray for genotyping polymorphisms related to xenobiotic metabolism and DNA repair. Landi, S., Gemignani, F., Gioia-Patricola, L., Chabrier, A., and Canzian, F. BioTechniques 2003, Vol. 35, pp. 816-827
  3. Reliable Detection of beeta-Thalasseemia and G6PDMutations by a DNA Microarray. Gemignani F. et al., Kurg A., Tonisson N., Galanello R. et al. Clinical Chemistry 48, No.11, 2002 2051-2054
  4. A first-generation linkage disequilibrium map of human chromosome 22. Cardon L. R. et     al., Dawson E. et al., Abecasis R. G., Ganske R., Remm M. et al. , Zernant J. et al., Vilo J.  Nature 418, 544-548, August 2002
  5. Evaluating the arrayed primer extension resequencing assay of TP53 tumor suppressor gene. Neeme T�nisson, Jana Zernant, Ants Kurg, Hendrik Pavel, Georg Slavin, Hanno Roomere, Aune Meiel, Pierre Hainaut and Andres Metspalu Proc. Natl. Acad. Sci. USA, 2002, Vol. 99, Issue 8, 5503-5508.

Gastrocentrum Kirurgi K53
Karolinska Universitetssjukhuset Huddinge
S-141 46 Stockholm, Sweden
Telephone: + 46 8 585 800 / 828 06
Fax: + 46 8 585 864 50
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., This email address is being protected from spambots. You need JavaScript enabled to view it.

Curriculum vitae
Name: Johan Permert
Birth: 7.12.57

Brief CV Prof.Dr.med (MD, Ph.D.) Johan Permert (*7.12.57)
Present position: Full professor of surgery. Div.head for Upper Abdominal Surgery, Dept of Surgical Gastroenterology, Karolinska University Hospital, Director of Metabolic Research Laboratory, Novum, Karolinska Institutet, Stockholm, Sweden.

1976-1982Study of Medicine, Karolinska Institutet, Stockholm, Sweden.
1982-1988Training in Surgery. Köping and Motala, Sweden.
1990 1991Research fellow Department of Biomedical Sciences, Creighton University, Omaha, Nebraska, USA. Prof. Jutta Lüttges (key-person 2): Head of department of Pathology, full professor of pathology and molecular pathology, expertise in pancreatic pathology, group leader oenological research projects. As expert in diagnostic pathology and morphological classifications of pancreatic tumours will be involved in.
1988-1990Scientific and clinical assistant, Department of Surgery, Linköping University Hospital, Linköping.
Scientific and clinical assistant, Department of Surgery, Linköping University Hospital, Linköping.
1993Ph D, Department of Surgery, Linköping University.
1994-1999Scientific and clinical assistant, Department of Surgical Gastroenterology, Karolinska University Hospital, Stockholm.
1999-2005Division head, Upper abdominal Surgery, Department of Surgical Gastroenterology, Karolinska University Hospital, Stockholm.
2003-2005Professor of Surgery, Karolinska Institutet.
Board certifications/diplomas: General Surgery 1990